Sputnik Light, priced at less than $10 showed 79.4% efficacy, according to an analysis of data gathered 28 days after the shot was administered as part of Russia’s mass vaccination program between December 2020 and April 2021.
Russian authorities on Thursday approved ‘Sputnik Light’, a single-dose version of the ‘Sputnik V’ vaccine that will be priced at less than $10. Sputnik Light showed 79.4% efficacy, according to an analysis of data gathered 28 days after the shot was administered as part of Russia’s mass vaccination program between December 2020 and April 2021, the vaccine’s developers said in a statement. The authorities also said that this move would help accelerate the process of achieving herd immunity against the deadly virus.
Russian Direct Investment Fund (RDIF) CEO Kirill Dmitriev, one of the developers along with the Russian health ministry and Gamaleya National Research Center of Epidemiology and Microbiology said that this vaccine would be the key solution for many countries as it showed “100% protection against severe infections”. He also said that this vaccine will be manufactured in India, among other countries, in the coming months.
“We have partnerships with more than 20 producers in 10 countries and they will make both versions of the vaccine,” he said. Dmitriev also added that Sputnik Light works well with all existing mutations of the Coronavirus as it “includes all the mutations in its code”.
Phase I and II of the safety and immunogenicity study of Sputnik Light had demonstrated that it can elicit the development of antigen-specific IgG antibodies in 96.9% of individuals on the 28th day after vaccination, and that elicits the development of virus-neutralizing antibodies in 91.67% of individuals on the 28th day after immunization.
No serious adverse events were registered after vaccination with Sputnik Light, the statement said. The infection rate among vaccinated subjects from the 28th day from the date of the injection was 0.277%. Over the same period, the infection rate among unvaccinated adults was 1.349%.
The Phase III clinical study involving 7,000 people was conducted in multiple countries, including Russia, the UAE, and Ghana. The interim results are expected in May.
The Sputnik V vaccine is being manufactured in India by Hyderabad-based Dr. Reddy’s Laboratories and is expected to be rolled out soon.